Best Useful Articles

Reducing Breast Cancer Risk By Vigorous Exercise

Post-menopausal women who engage in moderate to vigorous exercise have a reduced risk of breast cancer. This comes from researchers writing the open access journal BMC Cancer who investigated the link between breast cancer and exercise. "With an estimated 182, 460 new cases diagnosed in the United States in 2008, breast cancer is recognized as the most common cancer affecting U.S. women" says Dr. Tricia M Peters from the U.S. National Cancer Institute, Bethesda, Maryland, who headed up an international team of researchers. Vigorous exercise has been hypothesized to reduce cancer risk for some time. However, this new study is one of the first prospective investigations to look at the importance of various intensities of exercise at different stages in an individual's life.

Vitamin D Expert Receives Award From North American Menopause Society

Michael Holick, PhD, MD, director of the Bone Healthcare Clinic and the Vitamin D, Skin and Bone Research Laboratory at Boston University School of Medicine BUSM recently received the 2009 NAMS/Upsher-Smith Laboratories, Inc.Vitamin D Research Award from the North American Menopause Society (NAMS). Holick was presented with the award during NAMS' 20th annual meeting in San Diego, California on September 30 - October 3, 2009. NAMS/Upsher-Smith Laboratories, Inc. Vitamin D Research Award recognizes an individual whose body of research has advanced the understanding of the role of vitamin D-either endogenous or exogenous-for peri-and postmenopausal women.

Clinical Trial Data Documenting Improved Menopause Symptoms

SE5-OH containing Natural S-equol, a novel soy germ-based ingredient in a supplement, improved menopausal symptoms, including significantly reducing hot flash frequency by nearly 59 percent, according to a peer-reviewed study in Japanese women. This key study was presented in an oral presentation at the North American Menopause Society (NAMS) 20th annual meeting. A second oral presentation reported peer-reviewed data that documented for the first time the pharmacokinetics, or absorption and distribution in the body, in U.S. menopausal women of S-equol when taken as a supplement using SE5-OH containing Natural S-equol. Development and ongoing research of SE5-OH containing Natural S-equol is conducted by the Saga Nutraceuticals Research Institute of Otsuka Pharmaceutical Co.

Study Looks At Clinical Trial That Tested Estrogen-Plus-Progestin Combination

Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study. The research, published in the Oct. 12 issue of the Archives of Internal Medicine, is based on data from more than 16, 000 participants in the Women's Health Initiative estrogen-plus- progestin clinical trial. This trial was abruptly halted in July 2002 when researchers found that healthy menopausal women on the combination therapy had an elevated risk for invasive breast cancer.

Nutri5 R And Brain Health Related To Treatment Of Menopausal Symptoms

Earlier this year, the BBC reported that "HRT - Hormone Replacement Therapy - can shrink women's brains"1, after a study was published which showed that brain volume in women taking HRT was smaller in two key areas involved in thinking and memory. This comes in addition to earlier results from the Women's Health Initiative (WHI) Memory Study2 that linked HRT to an increased risk of memory loss and dementia, and an article in the Lancet3 which concluded that HRT "substantially increases the risk of dementia of any cause and cognitive* decline" (* memory, thinking and understanding). This adds to the growing body of evidence that the risks of HRT far outweigh any perceived benefits, evidence that Nutri Pharma feels needs to be brought to the attention of the 150, 000 women in Norway and millions of women across Europe who are still being prescribed this treatment.

Depomed Reports Results From Two Phase 3 Clinical Trials Evaluating Non-Hormonal Therapy For Menopausal Hot Flashes

Depomed, Inc. (NASDAQ:DEPO) announced top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes. In the higher dose treatment arm of the two doses evaluated, the 1800mg dose achieved positive results at 4 weeks. All four co-primary endpoints of the 1800mg dose at 4 weeks demonstrated significant reductions in frequency and severity in both clinical trials (p-values ranged from 0.0001 to 0.004). Of the other four co-primary endpoints of the 1800mg dose at 12 weeks, one endpoint was positive (p=0.

Cutting Breast Cancer Risk And Treating Symptoms Of Menopause With Hormone Mix

The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk, Yale researchers report in an abstract presented at the American Society for Reproductive Medicine (ASRM) scientific meeting in Atlanta, Georgia, October 17-21. Women in menopause who have symptoms, but have not had a hysterectomy are currently treated with a combination of estrogen plus progestin hormone therapy, but this treatment comes with side effects, including a higher risk of breast cancer caused by the progestin. To find a better way of administering hormone therapy without the breast cancer risk, Hugh S.

Hormone Replacement Therapy Decreases Mortality In Younger Postmenopausal Woman

Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women. However, the 2002 publication of a major study, the Women's Health Initiative (WHI), indicated increased risk for certain outcomes in older women, without increasing mortality. This sparked debate regarding potential benefits or harm of HRT. In an article published in the November 2009 issue of The American Journal of Medicine, researchers conducted a meta-analysis of the available data using Bayesian methods and concluded that HRT almost certainly decreases mortality in younger postmenopausal women.

To Provide Stroke Protection, Estrogen Therapy Probably Needs To Be Given Soon After Menopause

For estrogen replacement to provide stroke protection, it likely must be given soon after levels drop because of menopause or surgical removal of the ovaries, scientists report in the Journal of Neuroscience. Animal studies indicate a "critical period" for estrogen replacement and that when therapy is delayed, estrogen receptors on brain cells are significantly diminished along with the neuroprotection estrogen typically conveys, according to scientists from the Medical College of Georgia, North China Coal Medical University and the University of Texas Health Sciences Center at San Antonio. "We looked at the controversy over whether estrogen is going to be beneficial after long periods without it and found the answer appears to be 'no, '" says Dr.

New Key To The Puzzle Of Hormone Therapy And Breast Cancer Uncovered By Scientists

The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. "Postmenopausal hormone treatment is associated with increased rates of benign breast biopsies, and early and late stages of cancer. Atypical ductal hyperplasia is associated with the use of postmenopausal hormone treatment and its rates have decreased with the decline in use of this treatment, " said researcher Tehillah Menes, M.D., who was the chief of breast service in the Department of Surgery at Elmhurst Hospital Center, New York, when this study was conducted.

Fast: [10]
Best Useful Articles © Dimitrov Dmitriy
Designer Dimitrov Dmytriy